Reactions with Proteins of Three Novel Anticancer Platinum(II) Complexes Bearing N-Heterocyclic Ligands.
Animals
Antineoplastic Agents
/ chemistry
Binding Sites
Cattle
Coordination Complexes
/ chemistry
Crystallography, X-Ray
Cytochromes c
/ chemistry
Horses
Humans
Ligands
Models, Molecular
Muramidase
/ chemistry
Platinum
/ chemistry
Protein Binding
Protein Domains
Ribonuclease, Pancreatic
/ chemistry
Spectrometry, Mass, Electrospray Ionization
/ methods
crystallography
mass spectrometry
platinum complexes
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
29 Sep 2021
29 Sep 2021
Historique:
received:
10
09
2021
revised:
22
09
2021
accepted:
27
09
2021
entrez:
13
10
2021
pubmed:
14
10
2021
medline:
3
11
2021
Statut:
epublish
Résumé
Three novel platinum(II) complexes bearing N-heterocyclic ligands, i.e., Pt2c, Pt-IV and Pt-VIII, were previously prepared and characterized. They manifested promising in vitro anticancer properties associated with non-conventional modes of action. To gain further mechanistic insight, we have explored here the reactions of these Pt compounds with a few model proteins, i.e., hen egg white lysozyme (HEWL), bovine pancreatic ribonuclease (RNase A), horse heart cytochrome c (Cyt-c) and human serum albumin (HSA), primarily through ESI MS analysis. Characteristic and variegate patterns of reactivity were highlighted in the various cases that appear to depend both on the nature of the Pt complex and of the interacting protein. The protein-bound Pt fragments were identified. In the case of the complex Pt2c, the adducts formed upon reaction with HEWL and RNase A were further characterized by solving the respective crystal structures: this allowed us to determine the exact location of the various Pt binding sites. The implications of the obtained results are discussed in relation to the possible mechanisms of action of these innovative anticancer Pt complexes.
Identifiants
pubmed: 34638887
pii: ijms221910551
doi: 10.3390/ijms221910551
pmc: PMC8508948
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Coordination Complexes
0
Ligands
0
Platinum
49DFR088MY
Cytochromes c
9007-43-6
Ribonuclease, Pancreatic
EC 3.1.27.5
hen egg lysozyme
EC 3.2.1.-
Muramidase
EC 3.2.1.17
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Italian Association for Cancer Research
ID : 19650
Références
Chem Commun (Camb). 2017 Oct 24;53(85):11622-11633
pubmed: 29019481
Chemistry. 2017 May 23;23(29):6942-6947
pubmed: 28071831
Bioorg Med Chem. 2017 Mar 15;25(6):1907-1913
pubmed: 28254366
Lancet Oncol. 2014 Dec;15(13):e625-e634
pubmed: 25456381
Dalton Trans. 2018 Jul 3;47(26):8716-8723
pubmed: 29904761
Eur J Pharm Biopharm. 2015 Jun;93:52-79
pubmed: 25813885
JAMA Oncol. 2018 Nov 1;4(11):1481-1482
pubmed: 30422250
Chem Rev. 2006 Jun;106(6):2224-48
pubmed: 16771448
J Biol Chem. 1946 Aug;164(2):563-8
pubmed: 21001153
Nat Rev Cancer. 2021 Jan;21(1):37-50
pubmed: 33128031
Dalton Trans. 2015 Jun 14;44(22):10392-8
pubmed: 25974859
Struct Dyn. 2014 Jun 17;1(3):034701
pubmed: 26798779
Proteins. 2002 Jan 1;46(1):97-104
pubmed: 11746706
Biomed Pharmacother. 2018 Dec;108:111-118
pubmed: 30218855
Front Pharmacol. 2020 Mar 20;11:343
pubmed: 32265714
Int J Mol Sci. 2020 Sep 21;21(18):
pubmed: 32967255
BMC Cancer. 2019 Nov 8;19(1):1065
pubmed: 31703646
Acta Crystallogr D Biol Crystallogr. 1996 May 1;52(Pt 3):505-17
pubmed: 15299672
Metallomics. 2017 Nov 15;9(11):1534-1547
pubmed: 28967006
Int J Mol Sci. 2019 Jan 26;20(3):
pubmed: 30691130
Int J Biol Macromol. 2020 Nov 15;163:970-976
pubmed: 32653380
Acta Crystallogr D Biol Crystallogr. 2011 Apr;67(Pt 4):293-302
pubmed: 21460447
Curr Top Med Chem. 2021;21(1):6-27
pubmed: 32579504